Codexis, Inc.
CDXSCodexis, Inc. is a biotechnology company specializing in enzyme engineering and development for pharmaceuticals, biofuels, and specialty chemicals. Founded in 2002, the company focuses on creating biocatalysts that enable sustainable manufacturing processes, improving efficiency and reducing environmental impact.
Company News
Codexis, a provider of enzymatic solutions for therapeutics manufacturing, will participate in the Cantor Global Healthcare Conference in New York on September 4, 2025, presenting a live webcast of their fireside chat.
Codexis presented data at TIDES USA showcasing its ECO Synthesis platform's ability to support siRNA manufacturing, including reduced purification costs, improved process performance, and potential to control stereochemistry. Three CDMOs also validated the transferability of Codexis' ligation processes.
Codexis announced that Byron Dorgan will retire from the company's Board of Directors, and the company is developing its proprietary ECO Synthesisâ„¢ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.
The Specialty Enzymes market is growing rapidly due to increasing applications in food, beverages, and pharmaceuticals. Advancements in science and increasing consumer knowledge of the benefits of health are key driving factors. The market is expected to reach USD 10.7 Billion by 2032, growing at a CAGR of 7.5%.
The global artificial sweeteners market is expected to grow at a CAGR of around 4% from 2024 to 2030, driven by the increasing demand for low-calorie foods due to the rising rates of diabetes, hypertension, and obesity, as well as ongoing research and development efforts leading to new product launches.
